Dichiarazione di accessibilità Salta la navigazione
  • Torna ai siti globali
  • +44 (0)20 7454 5110
  • GDPR
  • Giornalisti
  • Richiedi maggiori informazioni
PR Newswire: news distribution, targeting and monitoring
  • Notizie
  • Prodotti
  • Contatto
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Richiedi maggiori informazioni
    • Telefono

    • +44 (0)20 7454 5110 da 8 AM - 5 PM GMT

    • Contattaci
    • Contattaci

      +44 (0)20 7454 5110
      da 8 AM - 5 PM GMT

  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR
  • Richiedi maggiori informazioni
  • Giornalisti
  • GDPR

MENARINI DIAGNOSTICS DETECTS ALL COVID VARIANTS
  • USA - español
  • USA - Deutsch
  • Italia - Italiano
  • USA - Français

(PRNewsfoto/Menarini I.F.R.)

Notizia fornita da

Menarini Industrie Farmaceutiche Riunite

14 mar, 2022, 12:49 GMT

Condividi articolo

Share toX

Condividi articolo

Share toX

Menarini's novel CoronaMeltVAR test detects SARS CoV-2 and discriminates the potential presence of the Delta, Omicron BA.1 or Omicron BA.2 variants

FLORENCE, Italy, March 14, 2022 /PRNewswire/ -- The sub-variant Omicron 2 (BA.2), similar in some parts to the Omicron variant and in other parts to the Delta variant, is the subject of epidemiological studies and possibly of clinical relevance for the prescription of monoclonal antibodies to COVID-19 patients.

CoronaMeltVAR is a Real Time PCR molecular kit designed to detect positivity to any variant of SARS CoV-2 and simultaneously determine the presence of certain classes of variants. Based on the melting curve analysis principle, this system produces a "profile" or fingerprint of the viral genome, related to the Omicron and Delta variants.

In just 90 minutes, the kit can differentiate the potential presence of the Delta, Omicron BA.1 or Omicron BA.2 variants in a SARS CoV-2 positive sample with a single amplification and subsequent analysis of the melting curve, even on low viral load samples.

This rapid and cost effective pre-screening allows sequencing attention to be focused on samples already classified as suspicious, facilitating the in-depth investigation of the spread and pathogenicity of rare variants in the population such as, at present, the Omicron 2 (BA.2) variant.

All the samples thus classified into categories by the CoronaMeltVAR kit can then be confirmed by sequencing for an accurate definition of the molecular variant.

For more information, please visit https://www.menarinidiagnostics.com/en-us/Home/Laboratory-products/COVID-19/Viral-RNA-Detection/CoronaMelt-Var/Overview

A.Menarini Diagnostics, the Human Touch of Technology: more than 45 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world.
A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, it counts more than 17,000 employees and has a 2020 turnover of € 3.750 billion.
www.menarinidiagnostics.com

Logo - https://mma.prnewswire.com/media/1584634/Menarini_Logo.jpg

Modal title

Sempre da questa fonte

Il Gruppo Menarini annuncia che, al 67° Congresso Annuale dell'American Society of Hematology, presenterà nuovi dati su ELZONRIS® (tagraxofusp-erzs)

Il Gruppo Menarini annuncia che, al 67° Congresso Annuale dell'American Society of Hematology, presenterà nuovi dati su ELZONRIS® (tagraxofusp-erzs)

Il Gruppo Menarini ("Menarini"), azienda leader a livello internazionale nel settore farmaceutico e diagnostico, e Stemline Therapeutics, Inc....

Volpi Rosse Menarini, i fantastici dieci per la stagione 2025/26

Volpi Rosse Menarini, i fantastici dieci per la stagione 2025/26

Dieci talenti internazionali, età ed esperienze diverse alle spalle. Ad unirli la voglia di fare la differenza, in Italia e in Europa. Dopo...

Altri comunicati stampa da questa fonte

Esplora

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Infection Control

Infection Control

New Products & Services

New Products & Services

Comunicati stampa su argomenti simili

Contatta PR Newswire

  • +44 (0)20 7454 5110
    da 8 AM - 5 PM GMT

Siti globali

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brasile
  • Canada
  • Ceco
  • Danimarca
  • Finlandia
  • Francia
  • Germania

 

  • India
  • Indonesia
  • Israele
  • Italia
  • Messico
  • Medio Oriente
  • Middle East - Arabic
  • Olanda
  • Norvegia
  • Polonia

 

  • Portogallo
  • Russia
  • Slovacchia
  • Spagna
  • Svezia
  • Regno Unito
  • Stati Uniti

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Siti globali
  • Asia
  • Brasile
  • Canada
  • Ceco
  • Danimarca
  • Finlandia
  • Francia
  • Germania
  • India
  • Israele
  • Italia
  • Messico
  • Medio Oriente
  • Olanda
  • Norvegia
  • Polonia
  • Portogallo
  • Russia
  • Slovacchia
  • Spagna
  • Svezia
  • Regno Uniti
  • Stati Uniti
+44 (0)20 7454 5110
da 8 AM - 5 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.